Reqorsa®基因疗法生物标志物临床数据积极,将于2026年ASCO年会公布

美股速递
Apr 22

备受期待的Reqorsa®基因疗法在患者生物标志物方面的积极临床数据,即将在2026年美国临床肿瘤学会(ASCO)年会上正式发布。

这项关键数据的公布,预计将为评估该基因疗法的疗效与作用机制提供重要依据。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10